|
Clinical Trials Headlines
Revlimid (Lenalidomide) For Myeloma - Phase III Study Findings
An evaluation of lenalidomide's (Revlimid) long-term 'maintenance' efficacy for patients with multiple myeloma has demonstrated considerable improvements from the time to progression and overall survival for those suffering from this often-fatal form of hematologic cancer. The May 10 issue of the New England Journal of Medicine reports that Dr. Philip L...
Wed, 16 May 2012 00:00:00 PDT - Source:MedNewsToday
Global Medical Research Urgently Requires International Treaty
In this week's PLoS Medicine, a team of international experts argue that in order to improve the fairness, coherence, sustainability, and efficiency of medical research worldwide, an international treaty is required...
Tue, 15 May 2012 14:00:00 PDT - Source:MedNewsToday
Could A Compound Found In Red Wine And Red Grapes Change The Course Of Alzheimer's Disease?
A national, phase II clinical trial examining the effects of resveratrol on individuals with mild to moderate dementia due to Alzheimer's disease has begun as more than two dozen academic institutions recruit volunteers in the coming months. R. Scott Turner, M.D., Ph.D., director of Georgetown University Medical Center's Memory Disorders Program, is the lead investigator for the national study...
Mon, 14 May 2012 01:00:00 PDT - Source:MedNewsToday
Growth Of Hepatocellular Carcinoma Halted By Combining Two MTOR Inhibitors
The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumour cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research Institute (IDIBELL). The study results are been published on the online edition of the journal Science Translational Medicine...
Fri, 04 May 2012 01:00:00 PDT - Source:MedNewsToday
Stem Cell Therapy To Treat PAD In Clinical Trial
Research led by vascular surgeons at Dartmouth-Hitchcock may offer new hope to sufferers of peripheral artery disease, the cause of nearly 60,000 lower-limb amputations annually, through the use of a patient's own stem cells. Richard J...
Fri, 04 May 2012 01:00:00 PDT - Source:MedNewsToday
Registered Clinical Trials Criticized
In the May 2 issue of JAMA, a study reveals that clinical studies registered in clinicaltrials.gov between 2007-2010 are dominated by small, single-center trials. In addition, the studies include significant heterogeneity (different in nature, hard to compare) in methodological approaches, including the use of data monitoring committees, randomization, and blinding...
Fri, 04 May 2012 00:00:00 PDT - Source:MedNewsToday
Pulmonary Arterial Hypertension - Phase III SERAPHIN Outcome Study Meets Primary Endpoint
The initial analysis of Actelion's macitentan, a novel dual endothelin receptor antagonist that resulted from a tailored drug discovery process, has met its primary endpoint in a pivotal, long term, event-driven SERAPHIN Phase III trial...
Wed, 02 May 2012 05:00:00 PDT - Source:MedNewsToday
Researchers Urge More Patient-Centered Care For African-American Breast Cancer Survivors
African-American breast cancer survivors were satisfied with their cancer treatment, but most were never offered clinical trials opportunities or support services during or after their treatment, according to a study by a UC Davis Comprehensive Cancer Center researcher and her community partner, Rev. Tammie Dynse...
Wed, 02 May 2012 01:00:00 PDT - Source:MedNewsToday
Mismatch Between Global Disease Burden In Youths And Research Devoted To Pediatric Patients
Although children are more likely than adults to suffer from many diseases, few clinical trials are being conducted to test drugs in pediatric patients, according to a study presented at the Pediatric Academic Societies (PAS) annual meeting in Boston. Drug studies in children are important because children often respond differently to medications than adults...
Tue, 01 May 2012 01:00:00 PDT - Source:MedNewsToday
Significant Improvement In Disability Scores With Alemtuzumab
Genzyme presented additional data at the 64th Annual Meeting of the American Academy of Neurology from its Phase II CARE-MS II trial, which demonstrated that the Expanded Disability Status Scale (EDSS), i.e...
Fri, 27 Apr 2012 12:00:00 PDT - Source:MedNewsToday
Health Research Strategy Not Present In Many Nations
International experts have written in this week's issue of PLoS Medicine that even though medical research from low-and middle-income countries has steadily risen in the last few decades, many countries still fail to have anything similar resembling a health research strategy...
Thu, 26 Apr 2012 10:00:00 PDT - Source:MedNewsToday
Financial Conflicts Of Interest - Does Disclosure Worsen Bias?
Last month, PLoS Medicine published an article of an examination of the financial conflicts of interest of members of the American Psychiatric Association (APA), which is responsible for updating the Diagnostic and Statistical Manual of Mental Disorders (DSM)...
Thu, 26 Apr 2012 10:00:00 PDT - Source:MedNewsToday
Ultra-Long-Acting Insulin Degludec, Two Phase 3 Studies Published
Two Phase III studies, published in The Lancet, reveal that ultra-long-acting insulin degludec considerably reduced rates of nocturnal hypoglycemia in patients with type 1 and type 2 diabetes by 25%, compared to insulin glargine. Insulin degludec is an investigational compound developed by Novo Nordisk...
Mon, 23 Apr 2012 09:00:00 PDT - Source:MedNewsToday
New Evidence Is Helping Explain Additional Health Benefits Of Aspirin
Researchers in Canada, Scotland and Australia have discovered that salicylate, the active ingredient in aspirin, directly increases the activity of the protein AMPK (AMP-activated protein kinase), a key player in regulating cell growth and metabolism. AMPK which is considered a cellular fuel-gauge is switched on by exercise and the commonly used anti-diabetic medication metformin...
Sat, 21 Apr 2012 00:00:00 PDT - Source:MedNewsToday
Oral Cancer Detection Could Dramatically Increase With Saliva Test
A Michigan State University surgeon is teaming up with a Lansing-area dental benefits firm on a clinical trial to create a simple, cost-effective saliva test to detect oral cancer, a breakthrough that would drastically improve screening and result in fewer people dying of the world's sixth most common cancer...
Thu, 19 Apr 2012 01:00:00 PDT - Source:MedNewsToday
Cimzia Trial Shows Promise For Axial Spondyloarthritis And Ankylosing Spondylitis
According to UCB, certolizumab pegol achieved top-level results in a phase 3 study, which assessed the drug's efficacy and safety in patients with adult-onset active axial spondyloarthritis (AxSpA), a family of inflammatory rheumatic diseases, including ankylosing spondylitis (AS)...
Tue, 17 Apr 2012 10:00:00 PDT - Source:MedNewsToday
Warning Patients Of Impending Heart Attack Via Implantable Medical Device
More than 30% of the one million heart attack victims in the United States each year die before seeking medical attention. Although widespread education campaigns describe the warning signs of a heart attack, the average time from the onset of symptoms to arrival at the hospital has remained at 3 hours for more than 10 years...
Mon, 16 Apr 2012 00:00:00 PDT - Source:MedNewsToday
Flutemetamol For Alzheimer's - Phase 3 Results Released
According to GE Healthcare, the preliminary results of two Phase 3 studies of their investigational PET amyloid-imaging agent, [18F]flutemetamol, a GE Healthcare PET imaging agent developed to detect beta amyloid, both met their primary endpoints. Full results of both studies will be presented in the near future...
Fri, 13 Apr 2012 10:00:00 PDT - Source:MedNewsToday
Reversal Of Fragile X Syndrome In Mouse Model
A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism...
Thu, 12 Apr 2012 02:00:00 PDT - Source:MedNewsToday
Full Reports From Trials Should Be Public: Regulators Respond To Tamiflu Recommendations
The full clinical study reports that drugs that have been authorized for use in patients should be made publicly available in order to allow independent re-analysis of the benefits and risks of such drugs, according to leading international experts who base their assertions on their experience with Tamiflu (oseltamivir)...
Thu, 12 Apr 2012 00:00:00 PDT - Source:MedNewsToday
Postmenopausal Osteoporosis Phase 3 Trial Starts, Say Amgen And UCB
Osteoporosis affects more than 75 million people, with women being four times more at risk of developing the disease than men. Osteoporosis is a chronic, progressive and systemic disease, whereby the bone tissue deteriorates, losing mass and strength, which makes the bones more fragile and increases the risk of fractures...
Mon, 09 Apr 2012 12:00:00 PDT - Source:MedNewsToday
First Targeted Nanomedicine To Enter Human Clinical Studies
A team of scientists, engineers and physicians from Brigham and Women's Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects...
Sun, 08 Apr 2012 00:00:00 PDT - Source:MedNewsToday
Key Mechanism Behind Lymphoma Targeted By New Compound
Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings was announced at the AACR Annual Meeting 2012. "It's an exciting time to be involved in lymphoma treatment and research," says study author Mitchell Smith, M.D., Ph.D., director of Lymphoma Service at Fox Chase...
Thu, 05 Apr 2012 01:00:00 PDT - Source:MedNewsToday
Association Between Protein Aurora-A And Survival In Head And Neck Cancer
Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings were reported at the AACR Annual Meeting...
Wed, 04 Apr 2012 00:00:00 PDT - Source:MedNewsToday
Brodalumab For Moderate To Severe Psoriasis Moving Into Phase III
Results from a Phase II, randomized, double-blind, placebo-controlled, dose-ranging trial designed to evaluate the efficacy and safety of brodalumab (formerly AMG 827) in 198 patients with moderate to severe plaque psoriasis have been published in the New England Journal of Medicine...
Tue, 03 Apr 2012 09:00:00 PDT - Source:MedNewsToday
|
|
|
